# Biotechnology, Imaging and Drug Development Program (BIDD)

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA-IRVINE · 2024 · $62,520

## Abstract

BIOTECHNOLOGY, IMAGING, AND DRUG DEVELOPMENT PROGRAM
 ABSTRACT/PROJECT SUMMARY
The overarching goal of the reorganized Biotechnology, Imaging, and Drug Development (BIDD) Program is to
utilize novel computational, chemical, and engineering-based approaches to detect, diagnose, and treat cancer.
The BIDD Program evolved in response to the increasingly interdisciplinary nature of cancer research, spanning
chemistry, physics, mathematics, optics, engineering, biology, and medicine. The Program initiates concepts
through cross-disciplinary meetings at the pre-design phases; progresses through technology development
involving advanced chemistry, physics, and engineering; and proceeds through preclinical validation in model
systems and tissues before testing in clinical trials. The BIDD Program fuses two prior complementary programs
and provides leadership and structure to translate basic discoveries to the clinic. The formation of the Program
synergistically combines UCI's strengths in synthetic chemistry, bioengineering, and physics to maximize
translation of basic research. As the de facto technology development hub for the Cancer Center, BIDD reaches
out to other Cancer Center programs, Catchment Area stakeholders, and the investment community to build
interdisciplinary teams able to steer new technologies into cancer-relevant directions. The BIDD leadership
facilitates this process by establishing interdisciplinary teams of clinicians, physical scientists, and biologists to
guide each project from its earliest stages; assist in the design of validation experiments using appropriate
models (animal models with the Transgenic Mouse Facility, TMF), human tissues through the Experimental
Tissue Resource (ETR), and ex vivo tissue models); implement deep learning approaches for drug and
diagnostics development; provide infrastructure to complete IND-enabling studies; and design clinical trials to
test drug candidates and devices.
Membership: 78 Members from 24 Departments and 6 Schools
Funding: $3,003,969 NCI (Directs); $7,540,410 Other Peer-Reviewed (Directs)
Accruals: Interventional: 272; Treatment: 169; Institutional/Investigator-Initiated: 166
Publications: Total: 542; High Impact Journal: 101 (19%); Intra-programmatic: 107 (20%);
 Inter-programmatic: 109 (20%); Inter-Institutional: 262 (48%)

## Key facts

- **NIH application ID:** 10816408
- **Project number:** 5P30CA062203-26
- **Recipient organization:** UNIVERSITY OF CALIFORNIA-IRVINE
- **Principal Investigator:** Anand K Ganesan
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $62,520
- **Award type:** 5
- **Project period:** 1997-09-11 → 2027-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10816408

## Citation

> US National Institutes of Health, RePORTER application 10816408, Biotechnology, Imaging and Drug Development Program (BIDD) (5P30CA062203-26). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10816408. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*